Romidepsin and Erlotinib Hydrochloride in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer

To be eligible for study participation, patients must fulfill all of the following criteria: * Histologically confirmed locally advanced or metastatic (stage IIIB pleural effusion or stage IV) NSCLC; * Age ≥ 18 years; * Written informed consent; * Measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST); * ECOG (Eastern Cooperative Oncology Group ) performance status 0 to 1; * Serum potassium and magnesium greater than or equal to the lower limit of institutional normal range (electrolyte abnormalities may be corrected with supplementation to meet inclusion criteria); * Negative urine or serum pregnancy test on females of childbearing potential; * All women of childbearing potential must use an effective barrier method of contraception (an intrauterine contraceptive device \[IUCD\] or double barrier method using condoms or a diaphragm plus spermicide) during the treatment period and for at least 1 month thereafter. Male patients should use a barrier method of contraception during the treatment period and for at least 1 month thereafter. Hormonal methods of contraception such as the contraceptive pill or patch (particularly those containing ethinyl-estradiol) should be avoided due to a potential drug interaction (see Appendix D). * Adequate bone marrow, liver, and renal function as evidenced by * Hemoglobin ≥10 g/dL (transfusions and/or erythropoietin-stimulating agents are permitted) * Absolute neutrophil count (ANC) ≥1.5 x 109 cells/L • Platele…